Faculty Profiles - ZAMAMI Yoshito

Papers - ZAMAMI Yoshito

Division display 21 - 40 of about 331 ／ All the affair displays >>

大規模データベースを用いたチロシンキナーゼ阻害剤による心臓毒性リスクの評価

井川祐輔, 江角悟, 武田達明, 濱野裕章, 鍛治園誠, 西原茂樹, 村川公央, 座間味義人

The Journal of Toxicological Sciences 49 ( Suppl. ) S90 - S90 2024.7

Effect of Lipopolysaccharide on the Duration of Zolpidem-Induced Loss of Righting Reflex in Mice. Reviewed

Yudai Wada, Soichiro Ushio, Yoshihisa Kitamura, Yoshito Zamami, Toshiaki Sendo

Acta medica Okayama 78 ( 3 ) 227 - 235 2024.6

Language：English Publishing type：Research paper (scientific journal)

Zolpidem, a non-benzodiazepine hypnotic, is primarily used to treat insomnia. In a previous study, pior treatment with non-benzodiazepine receptor agonists was associated with inflammation. The present study aimed to clarify the association between the effects of zolpidem and inflammation in mice treated with lipopolysaccharide (LPS), a known model of inflammation. We assessed the zolpidem-induced loss of righting reflex (LORR) duration 24 h after LPS treatment in mice. Additionally, the expressions of γ-aminobutyric acid (GABA)A receptor subunit and K+-Cl- cotransporter isoform 2 (KCC2) mRNA in the hippocampus and frontal cortex were examined in LPS-treated mice. Pretreatment with LPS was associated with significantly prolonged duration of zolpidem-induced LORR compared to control mice. This effect was significantly attenuated by administering bicuculline, a GABAA receptor antagonist, or flumazenil, a benzodiazepine receptor antagonist, in LPS-treated mice. Compared to controls, LPS-treated mice showed no significant change in the expression of GABAA receptor subunits in the hippocampus or frontal cortex. Bumetanide, an Na+-K+-2Cl- cotransporter isoform 1 blocker, attenuated the extended duration of zolpidem-induced LORR observed in LPS-treated mice. LPS significantly decreased Kcc2 mRNA expression in the hippocampus and the frontal cortex. These findings suggest that inflammation increases zolpidem-induced LORR, possibly through a reduction in KCC2 expression.

DOI： 10.18926/AMO/67197

PubMed

researchmap

医薬品供給問題が採用医薬品に与える影響に関する調査後発医薬品の使用促進および代替薬の確保の点から

槇田崇志, 佐田光, 田中雄太, 濱野裕章, 西原茂樹, 村川公央, 座間味義人

ジェネリック研究 ( 第18回学術大会要旨集 ) 65 - 65 2024.5

薬剤師による探索的アプローチの実際～CQからRQへの変換と試験の組み立て方～小児がん治療における探求的アプローチ

岩田直大, 蔵田靖子, 田中雄太, 濱野裕章, 鍛治園誠, 座間味義人

日本臨床腫瘍薬学会雑誌 36 72 - 72 2024.5

薬剤師による探索的アプローチの実際～CQからRQへの変換と試験の組み立て方～小児がん治療における探求的アプローチ

岩田直大, 蔵田靖子, 田中雄太, 濱野裕章, 鍛治園誠, 座間味義人

日本臨床腫瘍薬学会雑誌 36 72 - 72 2024.5

薬剤師による探索的アプローチの実際～CQからRQへの変換と試験の組み立て方～医療データ解析を起点とした臨床研究の実践

新村貴博, 八木健太, 相澤風花, 石澤有紀, 濱野裕章, 合田光寛, 座間味義人, 石澤啓介

日本臨床腫瘍薬学会雑誌 36 70 - 70 2024.5

医薬品供給問題が採用医薬品に与える影響に関する調査後発医薬品の使用促進および代替薬の確保の点から

槇田崇志, 佐田光, 田中雄太, 濱野裕章, 西原茂樹, 村川公央, 座間味義人

ジェネリック研究 ( 第18回学術大会要旨集 ) 65 - 65 2024.5

副作用報告データベースを用いたベバシズマブのバイオシミラーの安全性に関する検討

槇田崇志, 藤井緑, 濱野裕章, 座間味義人

日本医薬品情報学会総会・学術大会講演要旨集 26回 132 - 132 2024.5

Adverse events of nivolumab plus ipilimumab versus nivolumab plus cabozantinib: a real-world pharmacovigilance study. Reviewed International journal

Yurie Oka, Jun Matsumoto, Tatsuaki Takeda, Naohiro Iwata, Takahiro Niimura, Aya Fukuma Ozaki, Kensuke Bekku, Hirofumi Hamano, Motoo Araki, Keisuke Ishizawa, Yoshito Zamami, Noritaka Ariyoshi

International journal of clinical pharmacy 46 ( 3 ) 745 - 750 2024.4

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: No head-to-head clinical trials have compared the differences in adverse events (AEs) between nivolumab plus ipilimumab (NIVO-IPI) and nivolumab plus cabozantinib (NIVO-CABO) in the treatment of metastatic renal cell carcinoma (mRCC). AIM: We analysed the two largest real-world databases, the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and the World Health Organization's VigiBase, to elucidate the differences in AEs between NIVO-IPI and NIVO-CABO. METHOD: In total, 40,376 and 38,022 records were extracted from FAERS and VigiBase, and 193 AEs were analysed. The reporting odds ratios (ROR) with 95% confidence interval were calculated using a disproportionality analysis (NIVO-CABO/NIVO-IPI). RESULTS: The reported numbers of immune-related AEs, including myocarditis, colitis, and hepatitis, were significantly higher with NIVO-IPI (ROR = 0.18 for FAERS and 0.13 for VigiBase). Contrarily, the reported numbers of other AEs, including gastrointestinal disorders (ROR = 2.68 and 2.92) and skin and subcutaneous tissue disorders (ROR = 2.94 and 3.55), considered to be potentiated by the combination of NIVO and CABO, were higher with NIVO-CABO. CONCLUSION: Our findings contribute to the selection and clinical management of NIVO-IPI and NIVO-CABO, which minimizes the risk of AEs for individual patients with mRCC by considering distinctive differences in the AE profiles.

DOI： 10.1007/s11096-024-01713-1

PubMed

researchmap

ためになる薬の話薬物相互作用肺癌希少フラクションの分子標的治療薬

奥田浩人, 黒田智, 濱野裕章, 座間味義人

岡山医学会雑誌 136 ( 1 ) 29 - 32 2024.4

Burden of depressive disorders in Vietnam from 1990 to 2019: A secondary analysis of the Global Burden of Disease Study 2019. Reviewed International journal

Quynh Thi Vu, Ko Harada, Yoshito Nishimura, Hideharu Hagiya, Elizabeth Tan, Odifentse Mapula E Lehasa, Yoshito Zamami, Toshihiro Koyama

Journal of psychiatric research 172 420 - 426 2024.4

Language：English Publishing type：Research paper (scientific journal)

Depressive disorders are among the leading causes of disability globally. However, information on the burden of depressive disorders in Vietnam is limited. We aimed to analyse the burden of depressive disorders in Vietnam from 1990 to 2019. Using data from the Global Burden of Disease Study 2019, prevalence and disability-adjusted life-years (DALYs) were used as indicators to analyse the burden of depressive disorders by age and sex. In 2019 in Vietnam, depressive disorders comprised 2629.1 thousand (95% uncertainty interval (UI): 2233.3-3155.9) estimated cases and 380.6 thousand (95% UI: 258.9-533.8) estimated DALYs. The crude prevalence rate of depressive disorders was higher among females than among males. The DALYs of depressive disorder accounted for a higher percentage of the total all-cause DALYs in the 10-64-year age group than in other age groups. Major depressive disorder was the largest contributor to the burden of depressive disorders. From 1990 to 2019, the crude prevalence and DALY rates per 100 000 population due to depressive disorders increased significantly, whereas age-standardised rates of prevalence and DALYs decreased significantly; the respective average annual percent changes were 0.88% (95% confidence interval: 0.87 to 0.89), 0.68% (0.66 to 0.70), -0.20% (-0.21 to -0.19), and -0.27% (-0.28 to -0.25). Although the age-standardised prevalence rate was lower than that seen globally, depressive disorders were considerable mental health issues in Vietnam. This study will help governments and policymakers to establish appropriate strategies to reduce the burden of these disorders by identifying the priority areas and individuals.

DOI： 10.1016/j.jpsychires.2024.02.041

PubMed

researchmap

ためになる薬の話薬物相互作用肺癌希少フラクションの分子標的治療薬

奥田浩人, 黒田智, 濱野裕章, 座間味義人

岡山医学会雑誌 136 ( 1 ) 29 - 32 2024.4

抗がん剤心毒性の統合的な理解～基礎から臨床まで～大規模医療情報データベースを用いた薬剤性心毒性の予防法の開発

濱野裕章, 座間味義人, 牛尾聡一郎, 新村貴博, 合田光寛, 石澤有紀, 石澤啓介

薬学雑誌 144 ( 3 ) 257 - 264 2024.3

Language：Japanese Publisher：(公社)日本薬学会

著者らの研究グループでは、薬剤性心毒性への対策を確立することを目標に、大規模な医療情報を活用した研究を行い、医療情報解析によって多数のリスク因子を特定し、それら因子を抑える薬剤について探索している。今回、これまでの研究成果を以下の項目に分けて紹介した。1)医療ビッグデータ解析によって抽出した免疫チェックポイント阻害薬(ICI)関連心筋炎のリスク因子(年齢、性別、薬物相互作用)。2)医療ビッグデータ解析およびオミクスデータベース解析によって抽出したドキソルビシン誘発心毒性における予防候補薬の評価。

researchmap

Other Link： https://search.jamas.or.jp/default/link?pub_year=2024&ichushi_jid=J01459&link_issn=&doc_id=20240426250003&doc_link_id=%2Fcs7yakug%2F2024%2F014403%2F004%2F0257-0264%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcs7yakug%2F2024%2F014403%2F004%2F0257-0264%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases. Reviewed International journal

Tatsuaki Takeda, Shiho Sugimoto, Jun Matsumoto, Naohiro Iwata, Akihiko Nakamoto, Aya Fukuma Ozaki, Hirofumi Hamano, Noritaka Ariyoshi, Yoshito Zamami

International journal of clinical pharmacy 46 ( 2 ) 536 - 541 2024.1

Authorship：Last author Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: Palbociclib and abemaciclib are cyclin-dependent kinase (CDK) 4/6 inhibitors currently used to treat breast cancer. Although their therapeutic efficacies are considered comparable, differences in adverse event (AE) profiles of the two drugs remain unclear. AIM: We analysed two real-world databases, the World Health Organization's VigiBase and the Food and Drug Administration Adverse Event Reporting System (FAERS), to identify differences in AE profiles of palbociclib and abemaciclib. METHOD: Data of patients with breast cancer receiving palbociclib or abemaciclib recorded until December 2022 were extracted from the VigiBase and FAERS databases. In total, 200 types of AEs were analysed. The reporting odds ratios were calculated using a disproportionality analysis. RESULTS: Cytopenia was frequently reported in patients receiving palbociclib, whereas interstitial lung disease and diarrhoea were frequently reported in those receiving abemaciclib. Moreover, psychiatric and nervous system disorders were more common in the palbociclib group, whereas renal and urinary disorders were more common in the abemaciclib group. CONCLUSION: This study is the first to show comprehensively the disparities in the AE profiles of palbociclib and abemaciclib. The findings highlight the importance of considering these differences when selecting a suitable CDK4/6 inhibitor to ensure safe and favourable outcomes for patients with breast cancer.

DOI： 10.1007/s11096-023-01687-6

PubMed

researchmap

レセプトデータを用いたダサチニブと胃酸分泌抑制薬の薬物相互作用に関する検討

亀沖真希, 牛尾聡一郎, 佐田光, 建部泰尚, 濱野裕章, 座間味義人

日本臨床薬理学会学術総会抄録集 44回 2 - I3 2024.1

ステロイドはバンコマイシン関連腎障害を予防するビッグデータ解析・基礎研究・臨床研究の統合による検討

中馬真幸, 合田光寛, 座間味義人, 濱野裕章, 武智研志, 石田俊介, 坂東貴司, 新村貴博, 近藤正輝, 石澤有紀, 田崎嘉一, 石澤啓介

日本臨床薬理学会学術総会抄録集 44回 2 - 2 2024.1

レセプトデータを用いたダサチニブと胃酸分泌抑制薬の薬物相互作用に関する検討

亀沖真希, 牛尾聡一郎, 佐田光, 建部泰尚, 濱野裕章, 座間味義人

日本臨床薬理学会学術総会抄録集 44回 2 - I3 2024.1

ステロイドはバンコマイシン関連腎障害を予防するビッグデータ解析・基礎研究・臨床研究の統合による検討

中馬真幸, 合田光寛, 座間味義人, 濱野裕章, 武智研志, 石田俊介, 坂東貴司, 新村貴博, 近藤正輝, 石澤有紀, 田崎嘉一, 石澤啓介

日本臨床薬理学会学術総会抄録集 44回 2 - 2 2024.1

Lysyl oxidase-like 4 promotes the invasiveness of triple-negative breast cancer cells by orchestrating the invasive machinery formed by annexin A2 and S100A11 on the cell surface. Reviewed International journal

Tetta Takahashi, Nahoko Tomonobu, Rie Kinoshita, Ken-Ichi Yamamoto, Hitoshi Murata, Ni Luh Gede Yoni Komalasari, Youyi Chen, Fan Jiang, Yuma Gohara, Toshiki Ochi, I Made Winarsa Ruma, I Wayan Sumardika, Jin Zhou, Tomoko Honjo, Yoshihiko Sakaguchi, Akira Yamauchi, Futoshi Kuribayashi, Eisaku Kondo, Yusuke Inoue, Junichiro Futami, Shinichi Toyooka, Yoshito Zamami, Masakiyo Sakaguchi

Frontiers in oncology 14 1371342 - 1371342 2024

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: Our earlier research revealed that the secreted lysyl oxidase-like 4 (LOXL4) that is highly elevated in triple-negative breast cancer (TNBC) acts as a catalyst to lock annexin A2 on the cell membrane surface, which accelerates invasive outgrowth of the cancer through the binding of integrin-β1 on the cell surface. However, whether this machinery is subject to the LOXL4-mediated intrusive regulation remains uncertain. METHODS: Cell invasion was assessed using a transwell-based assay, protein-protein interactions by an immunoprecipitation-Western blotting technique and immunocytochemistry, and plasmin activity in the cell membrane by gelatin zymography. RESULTS: We revealed that cell surface annexin A2 acts as a receptor of plasminogen via interaction with S100A10, a key cell surface annexin A2-binding factor, and S100A11. We found that the cell surface annexin A2/S100A11 complex leads to mature active plasmin from bound plasminogen, which actively stimulates gelatin digestion, followed by increased invasion. CONCLUSION: We have refined our understanding of the role of LOXL4 in TNBC cell invasion: namely, LOXL4 mediates the upregulation of annexin A2 at the cell surface, the upregulated annexin 2 binds S100A11 and S100A10, and the resulting annexin A2/S100A11 complex acts as a receptor of plasminogen, readily converting it into active-form plasmin and thereby enhancing invasion.

DOI： 10.3389/fonc.2024.1371342

PubMed

researchmap

The Association between PDE5 Inhibitors and Aneurysm/Arterial Dissection:A Pharmacovigilance Study Using WHO Safety Database. Reviewed

Koji Miyata, Yuki Izawa-Ishizawa, Takahiro Niimura, Hirofumi Hamano, Fuka Aizawa, Kenta Yagi, Kei Kawada, Yoshito Zamami, Mitsuhiro Goda, Keisuke Ishizawa

The journal of medical investigation : JMI 71 ( 1.2 ) 134 - 140 2024

Language：English Publishing type：Research paper (scientific journal)

Aneurysm and arterial dissection have been reported as adverse drug events, associated with angiogenesis inhibitors and fluoroquinolones. Specifically, several cases of severe arterial disease following cGMP-specific phosphodiesterase type 5 (PDE5) inhibitors usage have recently been reported. It is necessary to ascertain the risks of serious adverse events caused by PDE5 inhibitors. We aimed to evaluate the association of aneurysm and artery dissection with PDE5 inhibitors using VigiBase, which is a World Health Organization database of spontaneously reported adverse events, for explorative hypothesis-generating analysis. We performed disproportionality analysis using a dataset from inception in 1967 to December 2022 and calculated reporting odds ratios (ROR) between PDE5 inhibitors and arterial diseases. We extracted 195,839 reports on PDE5 inhibitors with 254 reports of arterial disease as adverse events from VigiBase. Disproportionality analysis showed disproportional signals for PDE5 inhibitors (ROR, 2.30;95% confidence intervals, 2.04-2.61);disproportional signals were detected in analyses restricting the lesion site to the aorta or cerebral arteries. From stratified analysis, disproportional signals were noted in females, as well as males, generally recognized as a risk factor for artery diseases. This real-world data analysis suggests that PDE5 inhibitors may play a role in the development of lethal arterial disease. J. Med. Invest. 71 : 134-140, February, 2024.

DOI： 10.2152/jmi.71.134

PubMed

researchmap

　 PREV - NEXT 　

< ZAMAMI Yoshito >

Papers - ZAMAMI Yoshito